Nuvalent (NUVL) Interest & Investment Income (2022 - 2026)
Nuvalent (NUVL) posted Interest & Investment Income of $12.9 million for Q1 2026, up 10.94% on a QoQ basis from $11.6 million in Q4 2025, and up 8.68% year-over-year from $11.8 million in Q1 2025.
Nuvalent (NUVL) Interest & Investment Income (2022 - 2026) Analysis & Trends
Nuvalent's Interest & Investment Income history runs 5 years deep, the most recent figure standing at $12.9 million for Q1 2026.
- Quarterly Interest & Investment Income rose 8.68% year-over-year to $12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.8 million (up 9.67% YoY) and the FY2025 annual result came in at $44.8 million, up 16.65% from the prior year.
- Interest & Investment Income was $12.9 million for Q1 2026 at Nuvalent, up from $11.6 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $13.1 million in Q4 2024 and bottomed at $139000.0 in Q1 2022.
- A 5-year average of $7.3 million and a median of $8.2 million in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 3510.07% — and 2025, when it declined 11.5%.
- Nuvalent's Interest & Investment Income stood at $3.2 million in 2022, then jumped by 156.82% to $8.2 million in 2023, then jumped by 60.3% to $13.1 million in 2024, then declined by 11.5% to $11.6 million in 2025, then increased by 10.94% to $12.9 million in 2026.
- Business Quant data shows NUVL's Interest & Investment Income at $12.9 million in Q1 2026, $11.6 million in Q4 2025, and $10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 12.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.86 Mn |
| Dec 31, 2025 | 11.59 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 11.12 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Dec 31, 2024 | 13.10 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 8.50 Mn |
| Dec 31, 2023 | 8.17 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 267,000.00 |
| Mar 31, 2022 | 139,000.00 |